MedPath

Prospective randomized trial to establish the optimal treatment regimen of rituximab for adult patients with steroid dependent and frequent-relapsing or steroid resistant nephrotic syndrome.

Phase 4
Recruiting
Conditions
ephrotic syndrome
Registration Number
JPRN-UMIN000019844
Lead Sponsor
Osaka General Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
64
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients diagnosed by renal biopsy as having any pathology other than minimal change disease or focal segmental glomerulosclerosis. 2)Patients with malignant disease or hematological disease. 3)Patients who are or may be pregnant, brest-feeding or hope to be pregnant during the study period.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of relapse (study period:5-7 years)
Secondary Outcome Measures
NameTimeMethod
1)Duration of complete remission 2)Adverse effect (infusion reaction, anaphylaxis, infectious disease, progressive multifocal leukoencephalopathy, exacerbation of hepatitis and fulminant hepatitis by hepatitis B virus reactivation, skin or mucous membrane symptom, interstitial pneumonia, gastrointestinal perforation or obstruction)
© Copyright 2025. All Rights Reserved by MedPath